mRNA Vaccines and Therapeutics Market Size Worth USD 253.83 Billion by 2034 | CAGR: 16.7%

The global mRNA vaccines and therapeutics market size is expected to reach USD 253.83 billion by 2034, according to a new study by Polaris Market Research. The report “mRNA Vaccines and Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Type (Self-Amplifying mRNA-Based Vaccines and Conventional Non-Amplifying mRNA-Based Vaccines), Application, Treatment Type, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The mRNA vaccines and therapeutics market has seen a rapid evolution, particularly with the emergence of the COVID-19 outbreak. Messenger RNA (mRNA) technology emerged as an approach for COVID-19 vaccine development, offering unprecedented speed and flexibility. This innovation has created the way for rapid vaccine production during the pandemic and holds immense potential for future vaccines and therapeutics for a wide array of diseases such as influenza, cancer, and HIV.

Traditional vaccine development often requires lengthy processes to identify the most suitable antigens, grow virus samples, and produce large quantities of vaccine doses. In contrast, mRNA technology allows for rapid sequencing of a pathogen's genetic code, followed by the synthesis of mRNA that encodes the required antigen. This means that mRNA vaccines can be developed for any infectious disease as soon as its genetic sequence is known. This capability has prompted the exploration of mRNA vaccines for diseases beyond COVID-19, including influenza and Zika virus.

Do you have questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/mrna-vaccines-and-therapeutics-market/request-for-sample

mRNA therapeutics are being explored for other applications, particularly in oncology. Several companies, including Moderna and BioNTech, have begun clinical trials for mRNA-based cancer vaccines, with promising early results. These vaccines may potentially be used to treat a variety of cancers, as standalone therapies or in combination with other treatments such as chemotherapy and immunotherapy.

mRNA Vaccines and Therapeutics Market Report Highlights

• In terms of application, the cancer segment is expected to grow at a rapid pace during the forecast period owing to the ability of mRNA technology to revolutionize cancer treatment by enabling the development of personalized cancer vaccines and cancer immunotherapies.  
• Based on type, the conventional non-amplifying mRNA-based vaccines segment dominated the mRNA vaccines and therapeutics market share in 2024 owing to their proven efficacy and widespread adoption during the COVID-19 outbreak.
• In the global market, North America held the largest revenue share in 2024 due to robust healthcare infrastructure, significant investments in research and development, and rapid advancements in mRNA technology.
• A few of the global key market players are Pfizer Inc.; Moderna, Inc.; BioNTech SE; GlaxoSmithKline; Daiichi Sankyo; BioNTech SE; CureVac N.V.; AstraZeneca; Ethris; Sanofi; Arcturus Therapeutics; Innovac Therapeutics; Kernal Biologics; Pantherna Therapeutics; pHion Therapeutics; Recode Therapeutics; Rejuvenation Technologies; RNAimmune; Strand Therapeutics; Walvax; and Ziphius Vaccines.

Polaris Market Research has segmented the mRNA vaccines and therapeutics market report on the basis of type, application, treatment type, end user, and region:

By Type Outlook (Revenue, USD Billion, 2020–2034)

• Self-Amplifying mRNA-Based Vaccines
• Conventional Non-Amplifying mRNA-Based Vaccines

By Application Outlook (Revenue, USD Billion, 2020–2034)

• Cancer
• Infectious Diseases
• Autoimmune Diseases
• Others

By Treatment Type Outlook (Revenue, USD Billion, 2020–2034)

• Monoclonal Antibody
• Gene Therapy
• Cell Therapy
• Other

By End User Outlook (Revenue, USD Billion, 2020–2034)

• Research Laboratories and Organizations
• Hospitals
• Clinics
• Others

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

mRNA Vaccines and Therapeutics Market Report Scope